Printer Friendly

GEN-PROBE AND MOLECULAR BIOSYSTEMS SETTLE PATENT LITIGATION

 GEN-PROBE AND MOLECULAR BIOSYSTEMS SETTLE PATENT LITIGATION
 SAN DIEGO, Aug. 31 /PRNewswire/ -- Gen-Probe Inc. and Molecular Biosystems Inc. (NYSE: MB) (MBI) announced today they have settled their patent litigation concerning diagnostic test kits using genetic probe technology.
 MBI's wholly owned subsidiary Syngene Inc. agreed that Gen-Probe's U.S. Patent No. 4,851,330 for targeting ribosomal RNA is valid; agreed to be enjoined from manufacturing, using and selling infringing products including its current SNAP(TM) mycobacterium diagnostic kits; and agreed to pay Gen-Probe an undisclosed sum. Syngene's counterclaim that Gen-Probe's products infringed Syngene's U.S. Patent No. 4,948,882 was dismissed.
 Thomas A. Bologna, chairman, president and chief executive officer of Gen-Probe, and Vincent A. Frank, president and chief operating officer of Molecular Biosystems, said, "We are very pleased to end this dispute between two of San Diego's leading biotechnology companies."
 Gen-Probe Inc. is a leader in the development and commercialization of medical products based on genetic probe technology, and is ranked as one of the largest biotechnology companies in San Diego.
 Molecular Biosystems Inc. is a leader in the development and manufacturing of contrast agents for medical imaging, including ultrasound and magnetic resonance imaging. MBI's common stock is listed on the New York Stock Exchange under the symbol "MB."
 -0- 8/31/92
 /CONTACT: Thomas A. Bologna, chairman, president and CEO of Gen-Probe, 619-546-8000; or Vincent A. Frank, president and COO of Molecular Biosystems, 619-452-0681/
 (MB) CO: Gen-Probe Inc.; Molecular Biosystems Inc.; Syngene Inc. ST: California IN: MTC SU:


BP-JL -- SD001 -- 4772 08/31/92 06:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 31, 1992
Words:260
Previous Article:FIRST UNION TO PROVIDE MOBILE BANKING SERVICES
Next Article:S&T BANCORP BECOMES FEDERAL HOME LOAN BANK OF PITTSBURGH STOCKHOLDER
Topics:


Related Articles
GEN-PROBE AND MOLECULAR BIOSYSTEMS SETTLE PATENT LITIGATION
MOLECULAR BIOSYSTEMS ANNOUNCES LICENSE OF ITS ANTISENSE PATENTS
ImaRx PHARMACEUTICAL CORP. FILES SUIT AGAINST MOLECULAR BIOSYSTEMS INC. OVER TRADE SECRETS
GEN-PROBE FORMS NEW ANTISENSE THERAPEUTICS DIVISION; ANTICIPATES FIRST IND ON HIV ANTIVIRAL THIS YEAR
PE Biosystems Expands Strategic Alliance With Epoch Biosciences.
Epoch Biosciences Licenses its Eclipse Dark Quencher to Applied Biosystems.
Epoch Biosciences Expands License Agreement With Celera Diagnostics.
Epoch Biosciences Expands Eclipse(R) Dark Quencher Patent Portfolio.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters